



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

IDRA 21

Cat. No.:	HY-101528
CAS No.:	22503-72-6
Molecular Formula:	C ₈ H ₉ ClN ₂ O ₂ S
Molecular Weight:	232.69
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (1074.39 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		4.2976 mL	21.4878 mL	42.9756 mL
		5 mM		0.8595 mL	4.2976 mL	8.5951 mL
		10 mM		0.4298 mL	2.1488 mL	4.2976 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.94 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.94 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.94 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging ^[1] .
In Vitro	IDRA 21 (1-300 μM, 30 min) increases hippocampal neurons death in a dose-dependent manner ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IDRA 21 (0.15-10 mg/kg, p.o., once every 3 days, 3 weeks) improves delayed matching-to-sample (DMTS) task accuracy in young and aged rhesus monkeys^[1].

IDRA 21 (6-24 mg/kg, i.g., once time) increases G41 neuronal injury produced by global ischemia in adult rats^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Buccafusco JJ, et al. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. *Neuropharmacology*. 2004 Jan;46(1):10-22. doi: 10.1016/j.neuropharm.2003.07.002.

[2]. Yamada KA, et al. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. *Ann Neurol*. 1998 May;43(5):664-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA